RE: Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (XQ, WM); Tongji University School of Medicine, Shanghai, China (XQ, XZ); Department of Rehabilitation, the Second People's Hospital of Huai'an, Huai'an, China (LJJ); Department of Internal Medicine, Cangzhou Central Hospital, Cangzhou,China (YM).
Xiaolong
X
Qi
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (XQ, WM); Tongji University School of Medicine, Shanghai, China (XQ, XZ); Department of Rehabilitation, the Second People's Hospital of Huai'an, Huai'an, China (LJJ); Department of Internal Medicine, Cangzhou Central Hospital, Cangzhou,China (YM).
Li-Juan
LJ
Ji
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (XQ, WM); Tongji University School of Medicine, Shanghai, China (XQ, XZ); Department of Rehabilitation, the Second People's Hospital of Huai'an, Huai'an, China (LJJ); Department of Internal Medicine, Cangzhou Central Hospital, Cangzhou,China (YM).
Xiaoshen
X
Zhang
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (XQ, WM); Tongji University School of Medicine, Shanghai, China (XQ, XZ); Department of Rehabilitation, the Second People's Hospital of Huai'an, Huai'an, China (LJJ); Department of Internal Medicine, Cangzhou Central Hospital, Cangzhou,China (YM).
Yuxia
Y
Ma
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (XQ, WM); Tongji University School of Medicine, Shanghai, China (XQ, XZ); Department of Rehabilitation, the Second People's Hospital of Huai'an, Huai'an, China (LJJ); Department of Internal Medicine, Cangzhou Central Hospital, Cangzhou,China (YM).
Wang
W
Ma
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*
D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases